A Multicenter, Randomized, Open-label, Phase 2 Study of BMS-986504 Monotherapy in Advanced or Metastatic NSCLC with Homozygous MTAP Deletion After Progression on Prior Therapies
September 11, 2026
A Phase 2, Randomized, Open-label Study of Momelotinib in Participants with Anemia due to Low-risk Myelodysplastic Syndrome